Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review

Abdulrahman Ismaiel, Dan L Dumitraşcu, Abdulrahman Ismaiel, Dan L Dumitraşcu

Abstract

According to the World Health Organization, cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for approximately 18 million deaths per year. Nevertheless, the worldwide prevalence of metabolic diseases, such as type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease (NAFLD), also known to be common risk factors for CVD, have dramatically increased over the last decades. Chronic alcohol consumption is a major cause of chronic liver diseases (CLD) as well as being a major health care cost expenditure accounting for the spending of tremendous amounts of money annually. NAFLD has become one of the major diseases plaguing the world while standing as the most common cause of liver disease in the Western countries by representing about 75% of all CLD. Currently, the most common cause of death in NAFLD remains to be CVD. Several mechanisms have been suggested to be responsible for associating FLD with CVD through several mechanisms including low-grade systemic inflammation, oxidative stress, adipokines, endoplasmic reticulum stress, lipotoxicity and microbiota dysbiosis which may also be influenced by other factors such as genetic and epigenetic variations. Despite of all this evidence, the exact mechanisms of how FLD can causally contribute to CVD are not fully elucidated and much remains unknown. Moreover, the current literature supports the increasing evidence associating FLD with several cardiovascular (CV) adverse events including coronary artery disease, increased subclinical atherosclerosis risk, structural alterations mainly left ventricular hypertrophy, increased epicardial fat thickness, valvular calcifications including aortic valve sclerosis and mitral annular calcification and functional cardiac modifications mainly diastolic dysfunction in addition to cardiac arrhythmias such as atrial fibrillation and ventricular arrythmias and conduction defects including atrioventricular blocks and bundle branch blocks. Patients with FLD should be evaluated and managed accordingly in order to prevent further complications. Possible management methods include non-pharmacological strategies including life style modifications, pharmacological therapies as well as surgical management. This review aims to summarize the current state of knowledge regarding the pathophysiological mechanisms linking FLD with an increased CV risk, in addition to associated CV adverse events and current management modalities.

Keywords: alcoholic liver disease (ALD); cardiac arrhythmias; cardiovascular disease (CV disease); metabolic syndrome (MetS); non-alcoholic fatty liver disease (NAFLD).

Copyright © 2019 Ismaiel and Dumitraşcu.

Figures

Figure 1
Figure 1
Summary of potential pathophysiological mechanisms associating fatty liver disease with an increased cardiovascular risk. Fatty liver disease leads to multiple alterations in the human body as summarized in this figure, ultimately causing several complications including cardiovascular disease. Low grade systemic inflammation plays an essential role in the development of fatty liver disease. It can be explained by several intertwined factors such as diet, gut, microbiota, genes, visceral adipose tissue and liver. (ANGPTL, Angiopoietin like proteins; FGF21, Fibroblast growth factor 21; HDL, High-density lipoproteins; HMGB-1, High mobility group box 1; hsCRP, High sensitivity C-reactive protein; IL-1b, Interleukin 1b; IL-6, Interleukin 6; LDL, Low density lipoprotein; M1/M2, Macrophage phenotype 1/2 ratio; OxLDL, Oxidized low-density lipoprotein; PAI-1, Plasminogen activator inhibitor 1; PNPLA3, Patatin-like phospholipase domain containing protein 3; sdLDL, Small dense low-density lipoproteins; SeP, Selenoprotein P; sICAM-1, Soluble intercellular adhesion molecule-1; TM6SF2, Transmembrane 6 superfamily member 2; TMA, Trimethylamine; TMAO, Trimethylamine-N-Oxide; TNFα, Tumor necrosis factor a; VEGF, Vascular endothelial growth factor; VLDL, Very low-density lipoprotein).
Figure 2
Figure 2
Cardiovascular adverse events associated with fatty liver disease. These can include vascular involvement leading to an increased risk of coronary artery atherosclerosis, ischemic heart disease and an increased carotid intima media thickness. Other complications may include anatomical alterations such as valvular calcifications, functional alterations such as diastolic dysfunction as well as conduction system abnormalities leading to an increased risk of atrial and ventricular arrhythmias.
Figure 3
Figure 3
Management strategies in fatty liver disease with cardiovascular risk reduction. Management of fatty liver disease should be individualized to each patient accordingly. Non-pharmacological interventions are essential in the management of fatty liver disease through several lifestyle changes. Currently, no specific pharmacological therapies are approved for NAFLD or NASH. However, several therapeutic drugs were studied and demonstrated positive results in improving hepatic steatosis and liver enzymes as well as decreasing cardiovascular risk, while other drugs are showing promising results in undergoing late phase clinical trials. Surgical management is also possible in specific indicated cases.

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics−2014 update: a report from the American Heart Association. Circulation. (2014) 129:e28–92. 10.1161/01.cir.0000441139.02102.80
    1. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. (2011) 141:1249–53. 10.1053/j.gastro.2011.06.061
    1. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. (2015) 62:S38–46. 10.1016/j.jhep.2015.03.006
    1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. . Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. (2011) 9:524–530.e521; quiz e560. 10.1016/j.cgh.2011.03.020
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. (2016) 64:73–84. 10.1002/hep.28431
    1. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. (2008) 17:255–60. Available online at:
    1. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. . Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. (2010) 51:595–602. 10.1002/hep.23314
    1. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. (2015) 61:1547–54. 10.1002/hep.27368
    1. Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. (2010) 21:346–51. 10.1097/MOL.0b013e32833c1f41
    1. Sporea I, Popescu A, Dumitrascu D, Brisc C, Nedelcu L, Trifan A, et al. . Nonalcoholic fatty liver disease: status quo. J Gastrointestin Liver Dis. (2018) 27:439–48. 10.15403/jgld.2014.1121.274.quo
    1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. (2010) 363:1341–50. 10.1056/NEJMra0912063
    1. Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. (2018) 91:147–50. 10.15386/cjmed-993
    1. Macavei B, Baban A, Dumitrascu DL. Psychological factors associated with NAFLD/NASH: a systematic review. Eur Rev Med Pharmacol Sci. (2016) 20:5081–97. Available online at:
    1. Brunt EM, Janney CG, Dibisceglie AM, Neuschwander-Tetri B, Br B. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. (1999) 9:2476–4.
    1. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. (2001) 21:3–16.
    1. Chalasani N, Younossi Z. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. (2018) 67:328–57. 10.1002/hep.29367
    1. Monsour HP, Jr, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease–its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. (2012) 8:21–25.
    1. Burt Ad RM. Pathology of alcoholic liver disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, editors. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press; (1999). pp. 1179–84.
    1. Karl Seitz H., Mueller S., Dancygier H. Alcoholic liver disease. In: Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Berlin; Heidelberg: Springer; (2010). pp. 1111–1151. 10.1007/978-3-642-04519-6_34
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. (2009) 120:1640–5. 10.1161/circulationaha.109.192644
    1. Filipović B, Forbes A, Tepeš B, Dumitraşcu DL. Nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. (2018) 2018:2097435 10.1155/2018/2097435
    1. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. . Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. (2013) 25:147–51. 10.1097/MEG.0b013e32835a58b1
    1. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. . Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. (2009) 49:1537–44. 10.1002/hep.22845
    1. Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet. (2005) 18:365–70. 10.1111/j.1365-277X.2005.00634.x
    1. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol. (2013) 2013:124958. 10.1155/2013/124958
    1. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. . NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. (2002) 35:373–9. 10.1053/jhep.2002.30692
    1. Baliunas DO, Taylor BJ, Irving HEA. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabet Care. (2009) 32:2123e2132. 10.2337/dc09-0227
    1. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. (2009). 15:280–8. 10.3748/wjg.15.280
    1. Pflaum T, Hausler T, Baumung C, Ackermann S, Kuballa T, Rehm J, et al. . Carcinogenic compounds in alcoholic beverages: an update. Arch Toxicol. (2016) 90:2349–67. 10.1007/s00204-016-1770-3
    1. Chen C-J, Brown WM, Moomaw CJ, Langefeld CD, Osborne J, Worrall BB, et al. . Alcohol use and risk of intracerebral hemorrhage. Neurology. (2017) 88:2043–51. 10.1212/WNL.0000000000003952
    1. Costa P, Grassi M, Iacoviello L, Zedde M, Marcheselli S, Silvestrelli G, et al. . Alcohol intake and the risk of intracerebral hemorrhage in the elderly. MUCH-Italy. (2018) 91:e227–e235. 10.1212/wnl.0000000000005814
    1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. (2011) 29:415–45. 10.1146/annurev-immunol-031210-101322
    1. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. (2010) 52:1836–46. 10.1002/hep.24001
    1. Liu YL, Reeves HL, Burt AD, Tiniakos D, Mcpherson S, Leathart JB, et al. . TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. (2014) 5:4309. 10.1038/ncomms5309
    1. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. (2015). 35:270–90. 10.1055/s-0035-1562947
    1. Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology. (2015) 148:679–84. 10.1053/j.gastro.2015.01.038
    1. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. (2012) 33:1190–200. 10.1093/eurheartj/ehr453
    1. Francque SM, Van Der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. (2016) 65:425–43. 10.1016/j.jhep.2016.04.005
    1. Cakir E, Ozbek M, Colak N, Cakal E, Delibaşi T. Is NAFLD an independent risk factor for increased IMT in T2DM? Minerva Endocrinol. (2012) 37:187–93. Available online at:
    1. Bhatia L.S., Curzen N. P., Byrne C. D. (2012). Nonalcoholic fatty liver disease and vascular risk. Curr. Opin. Cardiol. 27, 420–428. 10.1097/HCO.0b013e328354829c
    1. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. (2009) 106:15430–5. 10.1073/pnas.0904944106
    1. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. (2010) 52:774–88. 10.1002/hep.23719
    1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. (2010) 51:679–89. 10.1002/hep.23280
    1. Gaziano JM, Hennekens CH, O'donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. (1997) 96:2520–25.
    1. Hurjui DM, Nita O, Graur LI, Mihalache L, Popescu DS, Hutanasu IC, et al. . Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Rev Med Chir Soc Med Nat Iasi. (2012) 116:692–9.
    1. Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, et al. . Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. (2013) 43:100–7. 10.1007/s12020-012-9712-1
    1. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, et al. . Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. (2013) 227:420–4. 10.1016/j.atherosclerosis.2013.01.013
    1. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. (2016). 65:1062–79. 10.1016/j.metabol.2015.11.006
    1. Smekal A, Vaclavik J. Adipokines and cardiovascular disease: a comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech. Repub. (2017) 161, 31–40. 10.5507/bp.2017.002
    1. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. (2006) 124:837–48. 10.1016/j.cell.2006.02.017
    1. Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res. (2009). 50 (Suppl) S340–345. 10.1194/jlr.R800056-JLR200
    1. Sanduzzi Zamparelli M, Compare D, Coccoli P, Rocco A, Nardone OM, Marrone G, et al. . The metabolic role of gut microbiota in the development of nonalcoholic fatty liver disease and cardiovascular disease. Int J Mol Sci. (2016) 17:E1225. 10.3390/ijms17081225
    1. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. . Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. (2014) 35:904–10. 10.1093/eurheartj/ehu002
    1. Tang CS, Zhang H, Cheung CYY, Xu M, Ho JCY, Zhou W, et al. . Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat Commun. (2015) 6:10206. 10.1038/ncomms10206
    1. Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, et al. . Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion. (2012) 86:107–13. 10.1159/000339344
    1. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. (2007) 92:3490–7. 10.1210/jc.2007-0482
    1. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. (2014) 20:8407–15. 10.3748/wjg.v20.i26.8407
    1. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. Lancet. (1987) 1:821–4. 10.1016/s0140-6736(87)91605-9
    1. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. (2006) 116:1813–22. 10.1172/jci29024
    1. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. . Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. (2008) 28:1039–49. 10.1161/atvbaha.107.159228
    1. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD St. Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. (2012) 32:945–50. 10.1111/j.1478-3231.2011.02753.x
    1. Blackett PR, Sanghera DK. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol. (2013) 7:65–81. 10.1016/j.jacl.2012.04.079
    1. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. (2012) 32:22–9. 10.1055/s-0032-1306423
    1. Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, et al. . Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging. (2010) 3:352–60. 10.1016/j.jcmg.2009.12.013
    1. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation. (2007) 116:1306–17. 10.1161/circulationaha.106.678375
    1. Oliveira A, Rodriguez-Artalejo F, Lopes C. Alcohol intake and systemic markers of inflammation–shape of the association according to sex and body mass index. Alcohol Alcohol. (2010) 45:119–25. 10.1093/alcalc/agp092
    1. Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, et al. . Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging. (2009) 2:692–700. 10.1016/j.jcmg.2009.03.009
    1. Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Cury RC, et al. . Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. (2009) 2:675–88. 10.1016/j.jcmg.2008.12.031
    1. Chang Y, Ryu S. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. (2018) 68:1667–75. 10.1136/gutjnl-2018-317666
    1. Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR. (2015). Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause. 22, 1323–1327. 10.1097/gme.0000000000000503
    1. Wolff L, Hofman A, Bos D, Krestin GP, Vernooij MW, Franco OH, et al. . Liver fat is related to cardiovascular risk factors and subclinical vascular disease: the Rotterdam Study. Eur Heart J-Card Img. (2016) 17:1361–7. 10.1093/ehjci/jew174
    1. Kim BJ, Cheong ES, Kang JG, Kim BS, Kang JH. Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: from the CAESAR study. J Clin Lipidol. (2016) 10:619–26.e611. 10.1016/j.jacl.2016.01.008
    1. Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin C, Loomba R. Association of nonalcoholic fatty liver disease with visceral adiposity but not coronary artery calcification in the elderly. Clin Gastroenterol Hepatol. (2016) 14:1337–44.e1333. 10.1016/j.cgh.2016.01.010
    1. Lee MK, Park HJ, Jeon WS, Park SE, Park CY, Lee WY, et al. . Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. Cardiovasc Diabetol. (2015) 14:88. 10.1186/s12933-015-0253-9
    1. Vanwagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, et al. . Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the coronary artery risk development in young adults study. Atherosclerosis. (2014) 235:599–605. 10.1016/j.atherosclerosis.2014.05.962
    1. Jung DH, Lee YJ, Ahn HY, Shim JY, Lee HR. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med. (2010) 48:1829–34. 10.1515/cclm.2010.349
    1. Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis. (2007) 18:433–6. 10.1097/MCA.0b013e3282583c0d
    1. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int. (2007) 27:891–4. 10.1111/j.1478-3231.2007.01531.x
    1. Acikel M, Sunay S, Koplay M, Gundogdu F, Karakelleoglu S. Evaluation of ultrasonographic fatty liver and severity of coronary atheroscledrosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg. (2009) 9:273–79. Available online at:
    1. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. . Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J Gastroenterol Hepatol. (2015) 30:1536–42. 10.1111/jgh.12992
    1. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med. (2010) 122:10–18. 10.3810/pgm.2010.01.2091
    1. O'leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. (1999) 340, 14–22. 10.1056/nejm199901073400103
    1. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. (2007) 115:459–467. 10.1161/circulationaha.106.628875
    1. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. . A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. (2013) 230:258–67. 10.1016/j.atherosclerosis.2013.07.052
    1. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. (2008) 49:600–7. 10.1016/j.jhep.2008.06.012
    1. Mishra S, Yadav D, Gupta M, Mishra H, Sharma P. A study of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. Indian J Clin Biochem. (2013) 28:79–83. 10.1007/s12291-012-0286-8
    1. Kim HJ, Lim CW, Lee JH, Park HB, Suh Y, Cho YH, et al. . Gender-based differences in the relationship between fatty liver disease and atherosclerosis. Cardiovasc J Afr. (2016) 27:281–6. 10.5830/cvja-2016-014
    1. Martinez-Alvarado Mdel R, Juarez-Rojas JG, Medina-Urrutia AX, Cardoso-Saldana GC, Gonzalez-Salazar Mdel C, Posadas-Sanchez R, et al. . Association of fatty liver with cardiovascular risk factors and subclinical atherosclerosis in a Mexican population. Rev Invest Clin. (2014) 66:407–14. Available online at:
    1. Li X, Shi H, Wang Z, Chang L, Zhang M, Dong X. Arterial stiffness is increased in nondiabetic, nonhypertensive postmenopausal women with nonalcoholic fatty liver disease. J Hypertens. (2017) 35:1226–34. 10.1097/hjh.0000000000001285
    1. Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V, et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab. (2009) 94:4103–6. 10.1210/jc.2009-0541
    1. Nahandi MZ, Khoshbaten M, Ramazanzadeh E, Abbaszadeh L, Javadrashid R, Shirazi KM, et al. . Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis. Gastroenterol Hepatol Bed Bench. (2014) 7:55–62.
    1. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. . Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. (2006) 29:1325–30. 10.2337/dc06-0135
    1. Mohammadi A, Bazazi A, Maleki-Miyandoab T, Ghasemi-Rad M. Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding. Int J Clin Exp Med. (2012) 5:251–6.
    1. Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. (2016) 246:13–20. 10.1016/j.atherosclerosis.2015.12.028
    1. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. role of visceral fat accumulation. Diabetes Care. (2004) 27:2498–500. 10.2337/diacare.27.10.2498
    1. Arinc H, Sarli B, Baktir AO, Saglam H, Demirci E, Dogan Y, et al. . Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis. UPS J Med Sci. (2013) 118:228–34. 10.3109/03009734.2013.814734
    1. Mckimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, et al. . Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol. (2008) 103:3029–35. 10.1111/j.1572-0241.2008.02188.x
    1. Kim JH, Kim SY, Jung ES, Jung SW, Koo JS, Kim JH, et al. Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients. Digestion. (2011) 84:149–55. 10.1159/000326854
    1. Qu B-G, Wang H, Liu Y-X, Jia Y-G, Su J-L, Wang Z-D, et al. . Causes of thickening of carotid intima-media thickness in patients with alcoholic liver disease: a prospective observational study. Medicine. (2015) 94:e1087–e1087. 10.1097/MD.0000000000001087
    1. Bao-Ge Q, Hui W, Yi-Guo J, Ji-Liang S, Zhong-Dong W, Ya-Fei W, et al. . The correlation and risk factors between carotid intima-media thickening and alcoholic liver disease coupled with helicobacter pylori infection. Sci Rep. (2017) 7:43059. 10.1038/srep43059
    1. Azzam H, Malnick S. Non-alcoholic fatty liver disease - the heart of the matter. World J Hepatol. (2015) 7:1369–76. 10.4254/wjh.v7.i10.1369
    1. Petta S, Argano C, Colomba D, Camma C, Di Marco V, Cabibi D, et al. . Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. (2015) 62:928–33. 10.1016/j.jhep.2014.11.030
    1. Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, et al. . Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. (2010) 211:182–6. 10.1016/j.atherosclerosis.2010.01.049
    1. Mahfouz RA, Gouda M, Galal I, Ghareb MS. Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. Echocardiography. (2019) 36:249–56. 10.1111/echo.14229
    1. Oguz D, Unal HU, Eroglu H, Gulmez O, Cevik H, Altun A. Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol. (2016) 16:974–79. 10.14744/AnatolJCardiol.2016.6706
    1. Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, et al. . Subclinical atherosclerosis is associated with epicardial fat thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis. (2016) 26:141–53. 10.1016/j.numecd.2015.10.013
    1. Sunbul M, Agirbasli M, Durmus E, Kivrak T, Akin H, Aydin Y, et al. . Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. (2014) 237:490–3. 10.1016/j.atherosclerosis.2014.10.004
    1. Psychari SN, Rekleiti N, Papaioannou N, Varhalama E, Drakoulis C, Apostolou TS, et al. . Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology. (2016) 67:41–8. 10.1177/0003319715576672
    1. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. . Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol. (1996) 31:279–84.
    1. Milić S, Lulić D, Štimac D, RuŽić A, Zaputovic L. Cardiac manifestations in alcoholic liver disease. Postgrad Med J. (2016) 92:235–9. 10.1136/postgradmedj-2015-133755
    1. Volzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, et al. . Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis. (2010) 209:606–10. 10.1016/j.atherosclerosis.2009.10.030
    1. Otto CM, Prendergast B. Aortic-valve stenosis–from patients at risk to severe valve obstruction. N Engl J Med. (2014) 371:744–56. 10.1056/NEJMra1313875
    1. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. (2018) 15:425–39. 10.1038/s41575-018-0010-0
    1. Markus MR, Baumeister SE, Stritzke J, Dorr M, Wallaschofski H, Volzke H, et al. . Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol. (2013) 33:1690–5. 10.1161/atvbaha.112.300556
    1. Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, et al. . Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE. (2014) 9:e88371. 10.1371/journal.pone.0088371
    1. Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, et al. . Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. (2015) 64:879–87. 10.1016/j.metabol.2015.04.003
    1. Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, et al. . Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. (2019) 39:758–69. 10.1111/liv.14044
    1. Zhang Y, Li P, Miao M, Liu Y, Pan Y, Xu L, et al. . Nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly chinese population: a cross-sectional study. (2018) 2018:5628749. 10.1155/2018/5628749
    1. Markus MR, Meffert PJ, Baumeister SE, Lieb W, Siewert U, Schipf S, et al. . Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: The Study of Health in Pomerania (SHIP). Atherosclerosis. (2016) 245:123–31. 10.1016/j.atherosclerosis.2015.12.023
    1. Mantovani A. NAFLD and risk of cardiac arrhythmias: is hyperuricemia a neglected pathogenic mechanism? Dig Liver Dis. (2018) 50:518–20. 10.1016/j.dld.2018.02.002
    1. Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G, et al. . Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care. (2016) 39:1416–23. 10.2337/dc16-0091
    1. Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, et al. . Nonalcoholic fatty liver disease is associated with qt prolongation in the general population. J Am Heart Assoc. (2015) 4. 10.1161/jaha.115.001820
    1. Mantovani A, Rigolon R, Pichiri I, Bonapace S, Morani G, Zoppini G, et al. . Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE. (2017) 12:e0185459. 10.1371/journal.pone.0185459
    1. Iscen S. RBBB is associated with an increased risk of NAFLD in young healthy individuals. Int J Cardiol. (2013) 168:4056–7. 10.1016/j.ijcard.2013.07.035
    1. Ozveren O, Dogdu O, Sengul C, Cinar V, Eroglu E, Kucukdurmaz Z, et al. . Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med Sci Monit. (2014) 20:1539–43. 10.12659/msm.890741
    1. Dyson JK, Anstee QM, Mcpherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Front Gastroenterol. (2014) 5:277–86. 10.1136/flgastro-2013-100404
    1. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA. (2004) 101:6659–63. 10.1073/pnas.0308291101
    1. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. . Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. (2015) 149:367–378.e365. 10.1053/j.gastro.2015.04.005
    1. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. (2007) 86:285–300. 10.1093/ajcn/86.2.285
    1. Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, et al. . Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches. Redox Biol. (2018) 15:467–79. 10.1016/j.redox.2018.01.009
    1. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. . The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. (2013) 59:138–43. 10.1016/j.jhep.2013.02.012
    1. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. (2016) 43:562–74. 10.1111/apt.13523
    1. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. (2017) 377:2063–72. 10.1056/NEJMra1503519
    1. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. (2012) 55:885–904. 10.1007/s00125-011-2446-4
    1. Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, et al. . Total body weight loss of >/= 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. (2015) 60:1024–30. 10.1007/s10620-014-3380-3
    1. Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. (2011) 108:1499–507. 10.1016/j.amjcard.2011.06.076
    1. Mahajan R, Lau DH, Sanders P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med. (2015) 25:119–26. 10.1016/j.tcm.2014.09.005
    1. Karimian S, Stein J, Bauer B, Teupe C. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab Syndr Obes. (2017) 10:19–25. 10.2147/dmso.s124541
    1. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J. (2005) 150:1233–39. 10.1016/j.ahj.2005.02.004
    1. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol. (2015) 31:195–202. 10.1016/j.cjca.2014.08.004
    1. Oni ET, Kalathiya R, Aneni EC, Martin SS, Blaha MJ, Feldman T, et al. . Relation of physical activity to prevalence of nonalcoholic fatty liver disease independent of cardiometabolic risk. Am J Cardiol. (2015) 115:34–9. 10.1016/j.amjcard.2014.09.044
    1. Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. . Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. (2017) 66:123–31. 10.1016/j.jhep.2016.08.019
    1. Kirwan JP, Solomon TP, Wojta DM, Staten MA, Holloszy JO. Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. (2009) 297:E151–156. 10.1152/ajpendo.00210.2009
    1. Van Der Heijden GJ, Wang ZJ, Chu Z, Toffolo G, Manesso E, Sauer PJ, et al. . Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc. (2010) 42:1973–80. 10.1249/MSS.0b013e3181df16d9
    1. Zhang H-J, He J, Pan L-L, Ma Z-M, Han C-K, Chen C-S, et al. . Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trialeffects of exercise on nonalcoholic fatty liver diseaseeffects of exercise on nonalcoholic fatty liver disease. JAMA Int Med. (2016) 176:1074–82. 10.1001/jamainternmed.2016.3202
    1. Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based Interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. Clin Gastroenterol Hepatol. (2016) 14:1398–411. 10.1016/j.cgh.2016.04.036
    1. Lin JS, O'connor E, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med. (2014) 161, 68–578. 10.7326/m14-0130
    1. Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, et al. . Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci. (2015) 129:1097–105. 10.1042/cs20150308
    1. Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int. (2017) 37:90–6. 10.1111/liv.13311
    1. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. (2015) 62:S65–75. 10.1016/j.jhep.2015.02.041
    1. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysisassociation of aspirin use for primary prevention of CVD with cardiovascular events and bleedingassociation of aspirin use for primary prevention of CVD with cardiovascular events and bleeding. JAMA. (2019) 321:277–87. 10.1001/jama.2018.20578
    1. Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. . Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. (2016) 43:734–43. 10.1111/apt.13515
    1. Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, et al. . Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. (2019). 10.1016/j.cgh.2019.04.061. [Epub ahead of print].
    1. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. . Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. (2004) 40:1222–5. 10.1002/hep.20420
    1. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. (2009) 15:942–54. 10.3748/wjg.15.942
    1. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. (2010) 52:79–104. 10.1002/hep.23623
    1. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. (2017) 13:297. 10.1038/nrneph.2017.16
    1. Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, et al. . Renin-angiotensin system inhibitors, Type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS ONE. (2016) 11:e0163069. 10.1371/journal.pone.0163069
    1. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. (2011) 43:617–49. 10.3109/07853890.2010.518623
    1. De Keyser CE, Koehler EM, Schouten JNL, Visser LE, Hofman A, Janssen HLA, et al. . Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis. (2014) 46:720–5. 10.1016/j.dld.2014.04.002
    1. Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. (2014) 45:52–7. 10.1016/j.arcmed.2013.12.003
    1. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. (2011) Cd004816. 10.1002/14651858.CD004816.pub4
    1. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ Br Med J. (2014) 349:g4379. 10.1136/bmj.g4379
    1. Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun C-C, Laskey R, et al. . Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. (2013) 168:3846–52. 10.1016/j.ijcard.2013.06.024
    1. Wiklund O, Pirazzi C, Romeo S. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep. (2013) 15:397. 10.1007/s11886-013-0397-8
    1. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. . Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. (2010) 376:1916–22. 10.1016/S0140-6736(10)61272-X
    1. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. . Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. (2015) 36:1012–22. 10.1093/eurheartj/ehv043
    1. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. (2014) 147:377–384.e371. 10.1053/j.gastro.2014.04.046
    1. Argo CK, Patrie JT, Lackner C, Henry TD, De Lange EE, Weltman AL, et al. . Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. (2015) 62:190–7. 10.1016/j.jhep.2014.08.036
    1. Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y, et al. . Effects of Omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis. Gastroenterol Res Pract. (2016) 2016:11. 10.1155/2016/1459790
    1. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. (2013) 1:57–64. 10.3892/br.2012.18
    1. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. (2013) 108:881–891; quiz 892. 10.1038/ajg.2013.5
    1. Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol. (2015). 7:1652–9. 10.4254/wjh.v7.i12.1652
    1. Mohan M, Al-Talabany S, Mckinnie AM, Mordi I, Singh JS, Gandy SJ, et al. Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus—The MET-REMODEL trial. Diabetes. (2018) 67, 167–OR. 10.2337/db18-167-OR
    1. Sanyal AJ, Chalasani N, Kowdley KV, Mccullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. (2010) 362:1675–85. 10.1056/NEJMoa0907929
    1. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. (2016) 165:305–15. 10.7326/m15-1774
    1. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. . Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. (2016) 387:679–90. 10.1016/s0140-6736(15)00803-x
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. (2016) 64:1388–402. 10.1016/j.jhep.2015.11.004
    1. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. . Effect of liraglutide therapy on liver fat content in patients with inadequately controlled Type 2 diabetes: the Lira-NAFLD Study. J Clin Endocrinol Metab. (2017) 102:407–15. 10.1210/jc.2016-2775
    1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. (2016) 375:311–22. 10.1056/NEJMoa1603827
    1. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. (2019) 45:213–23. 10.1016/j.diabet.2019.01.008
    1. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. . Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. (2016) 65:369–76. 10.1016/j.jhep.2016.04.021
    1. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. . Elafibranor, an agonist of the peroxisome proliferator–activated receptor–α and –δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. (2016) 150:1147–1159.e1145. 10.1053/j.gastro.2016.01.038
    1. Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. (2017) 37:634–47. 10.1111/liv.13270
    1. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. . Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. (2015) 385:956–65. 10.1016/s0140-6736(14)61933-4
    1. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. (2015) 19:429–37. 10.1007/s11605-014-2678-y

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera